EZH2 and cancer: Through multiomics analyses of clinical samples and biological experiments in cell and mouse models, we discovered a previously uncharacterized EZH2-DPP4-sICOSL-ICOS pathway that regulates cancer-CTL communication, tumor immune evasion, and the breakdown of chemoimmunotherapy.